ARTICLES BY LOUIS

• Cell Therapy The Engineering Miracle Of Our Times

  12/26/2022

  Vered Caplan, CEO, Orgenesis, unintentionally grew captivated in our cell-therapy industry. Her first love, though, is engineering. Since 2014, she’s been combining the rigors of one with the miracle-making of the second. “You don't manufacture cells. What you're doing is engineering and reprogramming cells,” she says

• Recession? We're Not Even Over COVID

  12/19/2022

  Executives say what began with the COVID-19 outbreak, and now the red flags raised over the state of the overall economy, feel like an inseparable supply-chain and outsourcing challenge. The unfortunate amalgam is expected to continue throughout 2023. Part 2 in our series ...

• When Drug Developers Convert To CDMOs

  12/14/2022

  “We have to change the team from doing drug development internally and internal research projects to those who are now client-centric and serving the pharmaceutical industry.” What we learn when sponsors become CDMOs.

• A New Year For Novo Nordisk's Wegovy Supply Challenges

  12/8/2022

  Those who follow this kind of news – and some who normally don’t – jumped on Novo Nordisk and Catalent for what is in fact a significant supply-chain challenge that came to light at the turn of the New Year. Now, a year later, we, too, take this up, but from a different perspective than previously presented.

• Prince Of Spray Drying Returns As Earl Of Dispersion

  12/7/2022

  Tim Scott traces the arc of spray drying from its advent to today’s advanced amorphous dispersion technology. Now he's back at it again, pushing the technology to even higher levels of accessibility and productivity.

• ATMP Report Identifies Outsourcing Realities

  11/28/2022

  A report from from The American Society of Gene & Cell Therapy (ASGCT) and Informa Pharma Intelligence speaks volumes about outsourcing without ever mentioning the word. Or “CDMO.” So we'll employ our synergistic powers to connect the data to your development and manufacturing relationships.

• Are You Ready For A Recession?

  11/21/2022

  CDMOs have facility utilization and operating profits. Biotechs have burn rates and investors. Pharma has budgets and profitability. The state of the economy affects all of these. In the past, we’ve seen outsourcing behaviors change acutely during economic downturns. Here's part one in a series with industry executives to get you ready for a downturn.

• Who's Afraid Of Their CDMO Getting Acquired?

  11/16/2022

  “It seems as soon as a new boutique or smaller CDMO – especially in the biologic space – can get established, one of the big guys is eating them up,” says Kelly Creighton, Citrus Pharmaceuticals. In this hard-hitting editorial, Creighton provides readers with some positive thoughts and solutions to overcome the challenges M&A may bring.

• CDMOs Still Limiting Access: COVID Or Convenience?

  11/11/2022

  Kelly Creighton of Citius Pharmaceuticals, Inc., likes to stay close to the CDMOs comprising his outsourcing strategy. "Prior to COVID," he says, "We were constantly going onsite." But now, is the continuing stringent policy regarding customer visits actually still wrapped around COVID, or are CDMOs staying restrictive for other reasons?

• Small Molecules And The Cost Of CDMO Services

  11/10/2022

  We should never take our eyes off the small-molecule market, and two surveys from ISR Reports suggests some interesting developments when it comes to costs and attitudes for outsourcing services in the sector.